search

Active clinical trials for "Schizophrenia"

Results 1681-1690 of 3086

Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With...

Acute Schizophrenia

The purpose of this study is to compare the effectiveness, safety and tolerability of three different doses of OPC-34712 with placebo in the treatment of acute schizophrenia in adults.

Completed13 enrollment criteria

Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients

Schizophrenia

The purpose of this study is changing (improving), after initiating various doses of Paliperidone ER on schizophrenia patients.

Completed22 enrollment criteria

N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis

Schizophrenic Psychoses

The investigators seek to examine the effect of add-on N-Acetyl-Cysteine (NAC) in the early phase of schizophrenia spectrum illness in collaboration with researchers Kim Do, PhD, and Philippe Conus, MD in Switzerland. Modifications of brain structure are thought to occur during the pre-illness phase and around the transition to psychosis. Therefore, studying new treatments that could target changes occurring during this period is of critical importance. Aims: Does add-on NAC treatment in early psychosis influence: positive and negative symptoms extrapyramidal side-effects of other medication plasma concentration of glutathione Mismatch Negativity, a physiological marker

Completed14 enrollment criteria

Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

Schizophrenia

This will be a randomized, double-blind, placebo-controlled study consisting of a screening period, a conversion phase (Phase 1), a stabilization phase (Phase 2), and a double-blind maintenance treatment phase (Phase 3), and a follow up period. Subjects may be either outpatients or inpatients between screening and through the time they reach stabilization at the end of Phase 2; hospitalization is not a study requirement. However, eligible subjects must be outpatients at the beginning of Phase 3. Subjects will be assessed weekly during Phase 1, weekly for the first 4 weeks of Phase 2 and 3, and biweekly for the remaining weeks during each of Phases 2 and 3. Subjects will be encouraged to call the investigators with any exacerbation of psychotic symptoms and/or any tolerability issues. The investigator will also have the option to phone the subjects and their guardian(s) at any time to ensure clinical stability. A data monitoring committee (DMC) will provide oversight for safety monitoring and reviewing the interim analysis. One interim analysis is planned after 75% of the total expected number of impending relapse events (28 events) are achieved and will be conducted by an independent data analysis center. The DMC will make a recommendation about stopping or continuing the study based on safety and efficacy reviews. The results of the interim analysis and individual subject data will remain blinded to the sponsor during the course of the study until the DMC determines that the study will conclude based on the results of the interim analysis, or the study is completed after 37 endpoint events.

Completed13 enrollment criteria

Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia

SchizophreniaSchizoaffective Disorder

Smokers with schizophrenia have more difficulties quitting smoking than smokers without a mental disorder. Varenicline (Champix) is a new stop smoking medication with a unique mechanism of action. It is a nicotine-like drug which is not addictive and not associated with the health risks of tobacco smoking. Varenicline (VAR) binds to sites in the brain called nicotine receptors that play an important role in nicotine dependence. People with schizophrenia have difficulties in concentrating and remembering. Scientists believe that people with schizophrenia use smoking to remedy their cognitive problems. We will test VAR to see if it improves cognitive problems in smokers with schizophrenia in comparison to non-mentally ill smokers to determine whether people with schizophrenia get direct benefit from this nicotine-like drug. It is hypothesized that VAR (in comparison to a placebo) will reduce aspects of cognitive impairment in smokers and nonsmokers with schizophrenia.

Completed28 enrollment criteria

Efficacy and Safety Study for Cognitive Deficits in Adult Subjects With Schizophrenia

Cognitive Deficits in Schizophrenia

This is an efficacy and safety study evaluating an experimental treatment for cognitive deficits in adults with schizophrenia.

Completed13 enrollment criteria

A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients...

Schizophrenia

The purpose of the study is to evaluate the safety, tolerability and treatment response of paliperidone palmitate administered as once-monthly injections to patients with schizophrenia.

Completed11 enrollment criteria

Safety and Efficacy of Cariprazine in Schizophrenia

Schizophrenia

The objective of this study is to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of acute exacerbation of schizophrenia.

Completed11 enrollment criteria

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia...

Schizophrenia

To evaluate the overall effectiveness of aripiprazole intramuscular (IM) depot as maintenance treatment in patients with schizophrenia.

Completed12 enrollment criteria

Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.

SchizophreniaSchizoaffective Disorder3 more

Since side effects of antipsychotics, dopamine D2 receptor blockers, frequently occur in older patients with schizophrenia and the risk is dose dependent, clinical guidelines universally advocate the use of lower doses. However, there is no report to test this dosing guideline with measurements of D2 receptor blockade caused by antipsychotics. In this study, dopamine D2 receptor occupancy will be measured, using Positron Emission Tomography (PET), in 40 patients aged 50 and older with schizophrenia-spectrum disorders before and after a gradual 40 % dose reduction of antipsychotics that was safely achieved in the past study while setting a target dose still above the lower limit of the dose range recommended in clinical guidelines for older patients. Our goal is to relate changes in clinical outcome, including subjective and objective clinical ratings, to dopamine D2 receptor occupancy, and compare these results with the data for younger patients in the literature.

Completed17 enrollment criteria
1...168169170...309

Need Help? Contact our team!


We'll reach out to this number within 24 hrs